A Phase 2, Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety-Tolerability of a Single Oral Dose of EP102 200mg or 400mg Self-Administered at Home By Adult Participants Experiencing Moderate to Severe Migraine Headache

Authors
Category Primary study
Registry of TrialsAustralian New Zealand Clinical Trials Registry
Year 2025
This article has no abstract
Epistemonikos ID: 9ba8d021a9dcfc05726ac373047a88c79d2b561d
First added on: Apr 17, 2025